Medication info
Rotacan Tablets 5/8 Milligrams

Rotacan Tablets 5/8 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Nokshim Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201702407 · Approved 2017.05.16 · Insurance code 643605430

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, suppression of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, treatment goals, and patient response, at intervals of 4 weeks or longer, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.
Child dose
Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Nokshim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, suppression of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • heart failure
  • hyperlipidemia
  • dyslipidemia
  • abnormal beta-lipoproteinemia
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used for patients who need to take both Candesartan Cilexetil and Rosuvastatin simultaneously. Candesartan Cilexetil is mainly used for patients with essential hypertension and heart failure with reduced left ventricular function, and is administered as an add-on therapy when ACE inhibitors are not sufficient or not well tolerated. Rosuvastatin is used as an adjunct when dietary and exercise regimens are not sufficient for controlling hyperlipidemia, particularly in patients at high risk for cardiovascular disease, by lowering cholesterol levels and delaying atherosclerosis progression. It also helps to reduce risks associated with stroke, myocardial infarction, and vascular reconstruction. Therefore, this medication is used to treat patients with hypertension, heart failure, hyperlipidemia, and cardiovascular risk.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, treatment goals, and patient response, at intervals of 4 weeks or longer, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.

Child dose

Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication may cause serious harm to the fetus or newborn if taken during pregnancy, so it should be stopped immediately if pregnancy is confirmed. It should not be used in individuals allergic to this medication or its components, those with severe liver dysfunction or active liver disease, pregnant or nursing women, and those with severe kidney impairment. Additionally, individuals with genetic conditions that prevent them from digesting lactose should not take this medication. Elderly individuals, those with high serum potassium levels, liver dysfunction, or cardiovascular diseases should exercise special caution when taking this medication. Patients who experience symptoms such as muscle pain or weakness should consult a doctor immediately, and it is advisable to have regular muscle-related examinations. This medication may affect liver function, so liver enzyme levels should be regularly monitored, and the medication should be discontinued if abnormalities are found. There may be interactions if this medication is taken with other drugs; therefore, it is essential to inform the doctor or pharmacist of any other medications being taken. Pregnant or nursing women should not take this medication, and women of childbearing potential should use appropriate contraceptive methods. Safety and efficacy for children have not been established, and it is not recommended for use in this population. Elderly patients are at risk of side effects from blood pressure reduction and should take caution when using this medication. In case of overdose, symptoms such as hypotension and dizziness may occur, and immediate consultation with healthcare professionals is necessary. During treatment with this medication, caution should be exercised while driving or operating machinery due to potential dizziness. Lastly, this medication should be stored out of the reach of children and kept in its original container for safety.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, hand fracture, elevated blood sugar, decreased serum sodium, hypoglycemia, nephrolithiasis, cough, dizziness, positional vertigo, milia, periodontitis, inflammation, foreign body sensation, nausea, chest discomfort, musculoskeletal pain, neck pain, cataract, tooth extraction, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, angioedema, thrombocytopenia, jaundice, hepatitis, liver dysfunction, hematuria, arthralgia, muscle cramps, gout, erectile dysfunction, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, polydipsia, sleep disorder, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, ageusia, rash, urticaria, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, myasthenia gravis, ocular myasthenia, hypotension, hyperkalemia, renal impairment, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, elevated AST, elevated γ-GTP, elevated liver enzymes, increased serum potassium, increased serum creatinine, increased blood pressure, cerebral infarction, spondyloarthritis myelopathy, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, productive cough, worsening hypertension, unstable blood pressure, vertigo, positional vertigo, adrenal insufficiency, shock, syncope, loss of consciousness, asthenia, hunger, cold sweat, hand tremor, decreased concentration, seizures, altered consciousness, intestinal vascular edema, vomiting, diarrhea, rash, urticaria, angioedema, thrombocytopenia, rhabdomyolysis, arthralgia, myalgia, low back pain, renal impairment, acute kidney failure, interstitial pneumonia, dyspnea, chest X-ray abnormalities, shock, blood pressure drop, syncope, loss of consciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.